$4.78
11.94% today
Nasdaq, Aug 12, 09:16 pm CET
ISIN
US00847G7051
Symbol
AGEN

Agenus Inc. Stock price

$4.27
-2.79 39.52% 1M
+1.06 33.02% 6M
+1.53 55.84% YTD
-0.86 16.76% 1Y
-48.13 91.85% 3Y
-65.01 93.84% 5Y
-143.12 97.10% 10Y
-652.81 99.35% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
-0.53 11.04%
ISIN
US00847G7051
Symbol
AGEN
Industry

Key metrics

Basic
Market capitalization
$117.1m
Enterprise Value
$134.1m
Net debt
$17.1m
Cash
$18.5m
Shares outstanding
26.6m
Valuation (TTM | estimate)
P/E
negative | 8.6
P/S
1.2 | 0.9
EV/Sales
1.4 | 1.0
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-144.2%
Return on Equity
69.7%
ROCE
1,245.7%
ROIC
-
Debt/Equity
-0.1
Financials (TTM | estimate)
Revenue
$99.5m | $129.7m
EBITDA
$-87.7m | $-148.1m
EBIT
$-100.9m | $31.5m
Net Income
$-190.8m | $13.2m
Free Cash Flow
$-146.3m
Growth (TTM | estimate)
Revenue
-38.4% | 25.3%
EBITDA
29.2% | -33.3%
EBIT
27.0% | 125.3%
Net Income
20.4% | 105.8%
Free Cash Flow
31.0%
Margin (TTM | estimate)
Gross
99.5%
EBITDA
-88.2% | -114.2%
EBIT
-101.4%
Net
-191.7% | 10.2%
Free Cash Flow
-147.0%
More
EPS
$-7.8
FCF per Share
$-5.5
Short interest
8.4%
Employees
316
Rev per Employee
$330.0k
Show more

Is Agenus Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Agenus Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Agenus Inc. forecast:

7x Buy
64%
4x Hold
36%

Analyst Opinions

11 Analysts have issued a Agenus Inc. forecast:

Buy
64%
Hold
36%

Financial data from Agenus Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
100 100
38% 38%
100%
- Direct Costs 0.52 0.52
43% 43%
1%
99 99
38% 38%
99%
- Selling and Administrative Expenses 71 71
9% 9%
71%
- Research and Development Expense 133 133
40% 40%
134%
-88 -88
29% 29%
-88%
- Depreciation and Amortization 13 13
9% 9%
13%
EBIT (Operating Income) EBIT -101 -101
27% 27%
-101%
Net Profit -191 -191
20% 20%
-192%

In millions USD.

Don't miss a Thing! We will send you all news about Agenus Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Agenus Inc. Stock News

Neutral
Business Wire
one day ago
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today reports financial results for the second quarter of 2025 and highlighted major clinical, regulatory, and operational milestones supporting the advancement of its botensilimab (BOT) and balstilimab (BAL) immunotherapy combination. Botensilimab is a ne...
Neutral
Business Wire
12 days ago
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its second quarter 2025 financial results before the market opens on Monday, August 11, 2025. Agenus will then host a stakeholder briefing in late August to spotlight key strategic plans, data milestones and provide a comprehensive update on the gl...
Neutral
Business Wire
18 days ago
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that four abstracts highlighting clinical progress across its botensilimab and balstilimab immunotherapy programs have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2025, taking place in Berlin, Germany from October 17-21. The highlight is an ...
More Agenus Inc. News

Company Profile

Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.

Head office United States
CEO Garo Armen
Employees 316
Founded 1994
Website agenusbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today